SC 13G/A

Names of reporting persons

Corriente Advisors, LLC

Check the appropriate box if a member of a group (see instructions)

(a) ☐ (b) ☐

SEC use only

Citizenship or place of organization

Delaware

0001193125-21-043215.txt : 20210216 0001193125-21-043215.hdr.sgml : 20210216 20210216062656 ACCESSION NUMBER: 0001193125-21-043215 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 GROUP MEMBERS: CORRIENTE MASTER FUND II, LP GROUP MEMBERS: MARK L. HART III SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CATABASIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001454789 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88910 FILM NUMBER: 21632099 BUSINESS ADDRESS: STREET 1: 100 HIGH STREET STREET 2: 28TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-349-1971 MAIL ADDRESS: STREET 1: 100 HIGH STREET STREET 2: 28TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Corriente Advisors, LLC CENTRAL INDEX KEY: 0001406718 IRS NUMBER: 752939516 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1401 FOCH ST STREET 2: SUITE 100 CITY: FORT WORTH STATE: TX ZIP: 76107 BUSINESS PHONE: 8178700400 MAIL ADDRESS: STREET 1: 1401 FOCH ST STREET 2: SUITE 100 CITY: FORT WORTH STATE: TX ZIP: 76107 SC 13G/A 1 d100462dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13GA

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Catabasis Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

14875P206

(CUSIP Number)

December 31, 2020

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP No. 14875P206

CUSIP No. 14875P206

CUSIP No. 14875P206

Explanatory Note

This Amendment No. 1 (this “Amendment”) amends, in its entirety, the statement on Schedule 13G originally filed on February 23, 2018 (the “Schedule 13G”) by the Reporting Persons (defined below). This Amendment reflects that, as of the date hereof, each Reporting Person has ceased to be the beneficial owner of more than 5% of any class of securities of the Issuer. This Amendment is the final amendment to the Schedule 13G.

Item 1(a)

Name of issuer:

Catabasis Pharmaceuticals, Inc.

Item 1(b)

Address of issuer’s principal executive offices:

One Kendall Square, Bldg. 1400E, Suite B14202, Cambridge, MA 02139

Item 2(a)

Name of person filing:

This Schedule is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”)

Corriente Advisors, LLC (“Corriente Advisors”);

ii)

Corriente Master Fund II, LP (“Corriente Master Fund II”); and

iii)

Mark L. Hart III (“Mr. Hart”).

This Amendment relates to outstanding shares of common stock of the Issuer, par value $0.001 per share (“Shares”), as well as Shares issuable upon the exercise of warrants, in each case, that were previously directly held by Corriente Master Fund II. Corriente Advisors acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II. Corriente Advisors may be deemed to indirectly beneficially own securities held by Corriente Master Fund II. Mr. Hart is the Chairman and Chief Executive Officer of Corriente Advisors. Mr. Hart may be deemed to indirectly beneficially own securities held by Corriente Master Fund II. As of the date hereof, none of the Reporting Persons beneficially own any Shares or warrants exercisable for Shares.

Each Reporting Person declares that neither the filing of this Schedule nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any syndicate or group with respect to the Issuer or any securities of the Issuer.

Item 2(b)

Address or principal business office or, if none, residence:

The address of the principal business office of each of the Reporting Persons is 1401 Foch St, Suite 100, Fort Worth, TX 76107.

Item 2(c)

Citizenship:

Corriente Advisors is a Delaware limited liability company;

ii)

Corriente Master Fund II is a Cayman Islands limited partnership; and

iii)

Mr. Hart is a citizen of the United States of America.

Item 2(d)

Title of Class of Securities:

Common Stock, $0.001 par value per share

Item 2(e)

CUSIP No.:

14875P206

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)		☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)		☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)		☐ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)		☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)		☒ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)		☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)		☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)		☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)		☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

(j)		☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)		☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

Item 4.

Ownership

As of the date hereof, for each of the Reporting Persons:


(a) Amount beneficially owned:	0
(b) Percent of class:	0	%
(c) Number of shares as to which such person has:
(i) Sole power to vote or direct the vote:	0
(ii) Shared power to vote or direct the vote:	0
(iii) Sole power to dispose or to direct the disposition of:	0
(iv) Shared power to dispose or to direct the disposition of:	0

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 16, 2021

CORRIENTE ADVISORS, LLC

/s/ Matthew Gilman

Chief Financial Officer

CORRIENTE MASTER FUND II, LP

/s/ Matthew Gilman

Chief Financial Officer of Corriente Advisors, LLC, the Investment Manager of Corriente Master Fund II, LP

MARK L. HART III

/s/ Mark L. Hart III

EXHBIT INDEX


Exhibit		Page No.

A. Joint Filing Agreement		10

EX-99.A 2 d100462dex99a.htm EX-99.A EX-99.A

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, par value $0.001 per share, of Catabasis Pharmaceuticals, Inc. dated as of February 16, 2021 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

CORRIENTE ADVISORS, LLC

/s/ Matthew Gilman

Chief Financial Officer

CORRIENTE MASTER FUND II, LP

/s/ Matthew Gilman

Chief Financial Officer of Corriente Advisors, LLC, the Investment Manager of Corriente Master Fund II, LP

MARK L. HART III

/s/ Mark L. Hart III